Fispemifene acts via estrogen receptors and has tissue-selective estrogenic and/or antiestrogenic effects – it has antagonist activity in breast tissue and acts as an estrogen agonist in bone. Due to its low estrogenicity in male rats, it might also be applicable for men. Fispemifene exhibits both antiestrogenic and anti-inflammatory action in the prostate. It could be considered as a new therapeutic option in the treatment and prevention of prostatic inflammation. Fispemifene had been in phase II clinical trials for the oral treatment of hypogonadism.